36476-88-7

Basic information

• Product Name: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE
• Synonyms: 1-DiphenylMethyl-3-(aMino...;1-(Diphenylmethyl)-3-azetidinemethanamine;3-Aminomethyl-1-diphenylmethylazetidinemethylamine;[1-(diphenylmethyl)azetidin-3-yl]methanamine;C-(1-BENZHYDRYL-AZETIDIN-3-YL)-METHYLAMINE;(1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE;RARECHEM AL BW 0782;1-Benzhydrylazetidine-3-methanamine
• CAS NO: 36476-88-7
• Molecular Formula: C₁₇H₂₀N₂
• Molecular Weight: 252.35
• Mol File: 36476-88-7.mol

Chemical Properties

• Boiling Point: 359℃
• Flash Point: 158℃
• Appearance: /
• Density: 1.102
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.608
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE(36476-88-7)
• EPA Substance Registry System: (1-BENZHYDRYLAZETIDIN-3-YL) METHANAMINE(36476-88-7)

Safety Data

• Hazardous Substances Data: 36476-88-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(1-Benzhydrylazetidin-3-yl) methanamine is used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its unique structural attributes make it a valuable component in the development of new drugs and organic molecules with potential therapeutic applications.
Used in Chemical Research:
In the field of chemical research, (1-Benzhydrylazetidin-3-yl) methanamine is used as a subject of study to explore its properties, potential applications, and to understand its role in the synthesis of complex organic molecules. This research can lead to advancements in the creation of new compounds with specific functions and effects.
Used in Drug Development:
(1-Benzhydrylazetidin-3-yl) methanamine is utilized in drug development for its potential biological activity. Its unique structure may contribute to the discovery of new drugs with novel mechanisms of action, potentially leading to more effective treatments for various diseases and conditions.

InChI:InChI=1/C17H20N2/c18-11-14-12-19(13-14)17(15-7-3-1-4-8-15)16-9-5-2-6-10-16/h1-10,14,17H,11-13,18H2

Upstream product

• 36476-86-5 1-(1,1-diphenylmethyl)azetidine-3-carbonitrile 
• 33301-41-6 1-benzhydryl-3-azetidinyl methanesulfonate 
• 18621-17-5 1-(diphenylmethyl)-3-hydroxyazetidine 

Downstream Products

• 91189-19-4 [[1-(diphenylmethyl)-3-azetidinyl]methyl]-carbamic acid 1,1-dimethylethyl ester 
• 1412978-13-2 3-[bis-(tert-butoxycarbonyl)aminomethyl]-1-(diphenylmethyl)azetidine 
• 321890-21-5 [1-(1,1-diphenylmethyl)azetidin-3-ylmethyl]dimethylamine 
• 55438-74-9 (1-benzhydrylazetidin-3-yl)-n,N-dimethylmethylamine 

Relevant articles and documents

PYRAZOLE DERIVATIVE

Not available

8-Phenyl-6, 9-dihydro-[1,2,4] triazolo[3,4-i]purin-5-one derivatives

8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives of formula (I): wherein: R1, R2 and R3 each independently represent: hydrogen; an alkyl group which is unsubstituted or substituted by a hydroxy, alkoxy, alkylthio, amino, mono- or di-alkylamino, hydroxycarbonyl, alkoxycarbonyl, acylamino, carbamoyl or alkylcarbamoyl group; or a group of formula —(CH2)n—R6 wherein n is an integer from 0 to 4 and R6 represents: a cycloalkyl group; a phenyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino, nitro, cyano or trifluoromethyl groups; or a 3 to 7-membered ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring may be unsubstituted or substituted by one or more halogen atoms or hydroxy, phenyl, alkoxycarbonyl, amino, mono- alkylamino, di-alkylamino or hydroxycarbonyl groups or one or more alkyl groups which may in turn be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, hydroxyalkoxy, phenyl, alkoxycarbonyl, amino, mono- or di-alkylamino or hydroxycarbonyl groups; either R4 and R5 together with the nitrogen atom to which they are attached form a 3 to 7-membered ring comprising a total of from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring may be unsubstituted or substituted by one or more halogen atoms or hydroxy, oxoalkyl, carbamoyl, hydroxycarbonyl, alkoxycarbonyl, trifluoroacetyl, amino, mono- or di-alkylamino groups or an alkylene group, or one or more alkyl, alkenyl or alkynyl groups which may in turn be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, hydroxyalkoxy, amino or mono- or di-alkylamino groups, or R4 and R5 independently represent hydrogen, an amidino group or an alkyl, alkenyl or alkynyl group which may be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, alkylthio, amino, mono- or di-alkylamino groups, or R4 represents hydrogen or an alkyl group and R5 represents a group of formula —(CH2)n—R7 wherein n is an integer from 0 to 4 and R7 represents: a cycloalkyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino, alkylamido, nitro, cyano or trifluoromethyl groups; a phenyl group which may be unsubstituted or substituted by one or more halogen atoms or alkyl, hydroxy, alkylenedioxy, alkoxy, amino, mono- or di-alkylamino, nitro, cyano or trifluoromethyl groups; or a 3 to 7-membered ring comprising from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulphur, which ring may be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, phenyl, alkoxycarbonyl, amino, mono-alkylamino, di-alkylamino or hydroxycarbonyl groups or one or more alkyl groups which may be unsubstituted or substituted by one or more halogen atoms or hydroxy, alkoxy, hydroxyalkoxy, phenyl, alkoxycarbonyl, amino, mono- or di-alkylamino or hydroxycarbonyl groups; or a pharmaceutically acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as PDE 5 inhibitors.

Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression

The invention relates to the use of pharmacologically valuable pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides according to general formula (I) in the treatment of tumors or for immunosuppression.

Bis-piperidinyl-pyrimidin-2-ones as alpha 1a adrenergic receptor antagonists

Pyrimidinone, oxazolidinone, and (alkyl)aryl derivatives, their synthesis, and their use as alpha 1a adrenergic receptor antagonists are disclosed. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are

Alpha 1a adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.

Quantitative structure-activity relationships of antibacterial agents, 7-heterocyclic amine substituted 1-cyclopropyl-6,8-difluoro-4-oxoquinoline-3-carboxylic acids

Quantitative structure-activity relationships (QSAR) of various 7-(3-substituted-azetidin-1-yl)-1-cyclopropyl-6,8-difluoro-1,4-dihydro -4-oxoquinoline-3-carboxylic acids, 14-25, were studied to clarify the structural requirements for 3-substituted azetidi

7-Azetidinylquinolones as antibacterial agents. Synthesis and structure- activity relationships

A series of novel antibacterial quinolones and naphthyridones has been prepared which contain 7-azetidinyl substituents in place of the usual piperazine or aminopyrrolidine groups. These azetidinyl derivatives were evaluated for in vitro activity by deter

Antibacterial agents

Novel quinoline-carboxylic acids as antibacterial agents are described as well as methods for their manufacture, formulation, and use in treating bacterial infections including the description of certain novel intermediates used in the manufacture of the antibacterial agents.

Antibacterial agents

Novel naphthyridine-, quinoline- and benzoxazine-carboxylic acids as antibacterial agents are described as well as methods for their manufacture, formulation, and use in treating bacterial infections including the description of certain novel intermediates used in the manufacture of the antibacterial agents.